BIOCRYST PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.40 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2015-05-08
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-03-31 was $3.40M.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-12-31 was $3.22M, a 11.82% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-09-30 was $3.85M, a 79.27% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2014-06-30 was $2.00M, a 4673.81% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $6.82M.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was -$2.05M, a 199.08% decline from fiscal 2012.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2012 was $2.07M.
- BIOCRYST PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was -$10.73M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2015-03-31 | $3.40M 10-Q · filed 2015-05-08 | $6.62M derived: sum of 2 quarters · filed 2015-05-08 | $10.47M derived: sum of 3 quarters · filed 2015-05-08 | $12.47M derived: sum of 4 quarters · filed 2015-05-08 | ||
| 2014-12-31 | $3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $7.07M derived: sum of 2 quarters · filed 2015-03-02 | $9.07M derived: sum of 3 quarters · filed 2015-03-02 | $6.82M 10-K · filed 2015-03-02 | ||
| 2014-09-30 | $3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $5.85M derived: sum of 2 quarters · filed 2014-11-07 | $3.60M 10-Q · filed 2014-11-07 | $6.48M derived: sum of 4 quarters · filed 2015-05-08 | ||
| 2014-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$247.00K 10-Q · filed 2014-08-08 | $2.63M derived: sum of 3 quarters · filed 2015-05-08 | $4.78M derived: sum of 4 quarters · filed 2015-05-08 | ||
| 2014-03-31 | -$2.25M 10-Q · filed 2015-05-08 | $624.00K derived: sum of 2 quarters · filed 2015-05-08 | $2.77M derived: sum of 3 quarters · filed 2015-05-08 | $2.81M derived: sum of 4 quarters · filed 2015-05-08 | ||
| 2013-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $5.02M derived: sum of 2 quarters · filed 2015-03-02 | $5.07M derived: sum of 3 quarters · filed 2015-03-02 | -$2.05M 10-K · filed 2015-03-02 | ||
| 2013-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $2.19M derived: sum of 2 quarters · filed 2014-11-07 | -$4.92M 10-Q · filed 2014-11-07 | $922.00K derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$7.07M 10-Q · filed 2014-08-08 | -$1.23M derived: sum of 3 quarters · filed 2015-03-02 | -$2.43M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | -$7.11M 10-Q · filed 2014-05-09 | -$1.27M derived: sum of 2 quarters · filed 2015-03-02 | -$2.47M derived: sum of 3 quarters · filed 2015-03-02 | -$2.25M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2012-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $4.64M derived: sum of 2 quarters · filed 2015-03-02 | $4.86M derived: sum of 3 quarters · filed 2015-03-02 | $2.07M 10-K · filed 2015-03-02 | ||
| 2012-09-30 | -$1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$987.00K derived: sum of 2 quarters · filed 2013-11-08 | -$3.78M 10-Q · filed 2013-11-08 | -$4.76M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-06-30 | $217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | -$2.58M 10-Q · filed 2013-08-08 | -$3.55M derived: sum of 3 quarters · filed 2014-03-10 | -$5.28M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-03-31 | -$2.79M 10-Q · filed 2013-05-09 | -$3.77M derived: sum of 2 quarters · filed 2014-03-10 | -$5.49M derived: sum of 3 quarters · filed 2014-03-10 | -$7.20M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2011-12-31 | -$979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | -$2.70M derived: sum of 2 quarters · filed 2014-03-10 | -$4.41M derived: sum of 3 quarters · filed 2014-03-10 | -$10.73M 10-K · filed 2014-03-10 | ||
| 2011-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$3.43M derived: sum of 2 quarters · filed 2012-11-08 | -$9.75M 10-Q · filed 2012-11-08 | -$9.71M 10-Q · filed 2011-11-03 | -$2.23M derived: sum of 4 quarters · filed 2013-03-11 | |
| 2011-06-30 | -$1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$8.03M 10-Q · filed 2012-08-08 | -$8.00M 10-Q · filed 2011-08-04 | -$507.00K derived: sum of 3 quarters · filed 2013-03-11 | $4.64M derived: sum of 4 quarters · filed 2013-03-11 | |
| 2011-03-31 | -$6.32M 10-Q · filed 2012-05-08 | $1.20M derived: sum of 2 quarters · filed 2013-03-11 | $6.35M derived: sum of 3 quarters · filed 2013-03-11 | |||
| 2010-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $12.67M derived: sum of 2 quarters · filed 2013-03-11 | -$9.48M 10-K · filed 2013-03-11 | |||
| 2010-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$17.01M 10-Q · filed 2011-11-03 | ||||
| 2010-06-30 | -$22.16M 10-Q · filed 2011-08-04 | |||||
| 2009-12-31 | $20.22M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |